RGNX REGENXBIO Inc.

18.00
-0.65  -3%
Previous Close 18.65
Open 18.55
Price To book 2.65
Market Cap 554.78M
Shares 30,821,000
Volume 102,172
Short Ratio 6.59
Av. Daily Volume 304,967

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 enrollment to be initiated 2H 2017.
RGX-111
Mucopolysaccharidosis Type I (MPS I)

Latest News

  1. REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
  2. Edited Transcript of RGNX earnings conference call or presentation 9-May-17 8:30pm GMT
  3. Regenxbio reports 1Q loss
  4. REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights
  5. Investor Network: REGENXBIO, Inc. to Host Earnings Call
  6. REGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : May 5, 2017
  7. Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences
  8. REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : May 4, 2017
  9. REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
  10. REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
  11. REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : April 5, 2017
  12. Blog Coverage Jazz Pharmaceuticals Inks License Agreement with Nippon Shinyaku
  13. REGENXBIO Enhances and Expands Scientific Leadership
  14. Regenxbio Leads Biotech Movers Ahead of Market's Open
  15. Regenxbio Sinks After Announcing Secondary Offering
  16. REGENXBIO Announces Pricing of Public Offering of Common Stock
  17. REGENXBIO Announces Proposed Public Offering of Common Stock
  18. 6 Stocks Trending Up With Big Volume
  19. REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017

SEC Filings

  1. 8-K - Current report 17870323
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826623
  3. 8-K - Current report 17826506
  4. 8-K - Current report 17784563
  5. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17761087
  6. DEF 14A - Other definitive proxy statements 17761046
  7. 8-K - Current report 17712824
  8. CT ORDER - Confidential treatment order 17708679
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17708097
  10. 424B5 - Prospectus [Rule 424(b)(5)] 17704267